Highlights

• Documents to Australian ethical committee and authority for next clinical study are finalised.
• The Covid19 pandemic has changed daily work for all involved in planning and executing filing of SER50 relevant documents to Australian ethical committee and authorities.
• The 100% owned Australian subsidiary Serodus (AUS) Pty Ltd was incorporated in August
• The Full Work Order with Parexel for the SER150 CL-009 was signed in September

Go to the report: Q3 2020 Report